adult vaccines market, company adult vaccines sales, country adult vaccines - worldwide analysis
TRANSCRIPT
Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines - Worldwide Analysis
Renub Researchwww.renub.com
Published: November, 2013Copyright © 2013 Renub Research – All Rights Reserved
Influenza … Cervical Cancer/ HPV … Hepatitis … Zoster Shingles … Pneumococcal … Measles, Mumps, Rubella and Varicella (MMRV) … Meningococcal …
Diphtheria, Tetanus, Pertussis (DTP) … Travel and Miscellaneous
© Renub Research Page 2 of 21
World Adult Vaccines Market – Market Overview
For much of the 20th century, vaccines were a pharmaceutical success story largely associated
with children. Aggressive immunization programs eradicated Polio and Smallpox among
developed nations and nearly eliminated Mumps, Pertussis, Measles, and other diseases. While
Pediatric Vaccines are an important market, it is now adults who are fueling growth of vaccine
products. The world adult vaccines market is expected to nearly double by 2020 from the
current figure of 2012.
Vaccination has played an enormous role in the prevention of disease, having had the greatest
impact on human health of any medical intervention. As a result, vaccine preventable diseases
and their resulting deaths are now rare in the developed world. However, the developing
nations have not benefited as much from the introduction of vaccines. Additionally, other
issues such as vaccine safety, shortages and bioterrorism continue to weigh upon the industry.
Renub Research study titled “Adult Vaccines Market, Company Adult Vaccines Sales,
Country Adult Vaccines - Worldwide Analysis” provides a comprehensive assessment of the
fast-evolving, high-growth of World Adult Vaccines Landscape. This 222 page report with 142
Figures and 15 Tables studies: 9 Adult Vaccines Market, 5 Companies Adult Vaccines Sales. In
total 28 Adult Vaccines have been researched for this report. This report is broadly divided into
11 chapters.
Adult Vaccines Market & Forecast data (2007 – 2020) covered in the report are as follows:
1. Influenza
2. Cervical Cancer/ HPV
3. Hepatitis
4. Zoster Shingles
5. Pneumococcal
6. Measles, Mumps, Rubella and Varicella (MMRV)
7. Meningococcal
8. Diphtheria, Tetanus, Pertussis (DTP)
9. Travel and Miscellaneous
© Renub Research Page 3 of 21
Companies’ Adult Vaccines Sales Share and Forecast data (2007 – 2020) covered in the
report
1. GlaxoSmithKline (GSK)
2. Sanofi Pasteur
3. Merck
4. Novartis
5. Pfizer
6. Others
(Chapter 1): Executive Summary
(Chapter 2): This Chapter is divided into 2 parts
A. Adult Vaccines Market and Forecast data from 2007 to 2020
B. Adult Vaccinated Number and Forecast from 2007 to 2020
(Chapter 3): This chapter is divided into 3 parts
A. Provides market share (percentage) of Adult Vaccines in the above mentioned vaccines
B. Provides market share (percentage) of Adult Vaccinated in the above mentioned
vaccines
C. Provides above mentioned companies market share in Adult vaccines.
(Chapter No. 4): This chapter is divided into 2 parts
A. Companies given above Sales Share (percentage) in Disease Wise Break up & Forecast
B. Adult Vaccines given above Companies Share and Forecast
© Renub Research Page 4 of 21
(Chapter 5): This chapter talks about all the 9 Adult Vaccines mentioned above. All these
vaccines have been further sub-divided into 4 parts
A. Adult Vaccine Market & Forecast
B. Number of Adults Being Vaccinated & Forecast
C. Number of Adult Vaccines Doses & Forecast
D. Number of Cases
(Chapter 6): This chapter studies mentioned above all the 5 companies Adult Vaccines Sales
and Forecast. The chapter further talks about the Company alliances with other Companies in
order to increase their vaccine sales.
(Chapter 7): This chapter studies mentioned above all the 5 companies’ Sales and Forecast
Disease Wise
(Chapter 8): This chapter provides Adult Vaccines Market and Forecast data of 8 Geographic
Regions Worldwide.
1. United States
2. North America/Caribbean
3. South America
4. Europe
5. Japan
6. India
7. China
8. Rest of the World (ROW)
(Chapter 9): This chapter comprises of important Mergers and Acquisitions happening in the
field of vaccines
© Renub Research Page 5 of 21
(Chapter 10): This chapter studies growth Factors Driving the Adult Vaccines Market. In total 8
growth topics have been discussed in this chapter.
(Chapter 11): This chapter studies Challenges/Hindrances faced by Adult Vaccines Market. In
total 7 challenges topics have been discussed in this chapter
Data Sources
This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-
printable sources like search engines, News websites, Government Websites, Trade Journals,
White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books,
Industry Portals, Industry Associations and access to more than 500 paid databases.
© Renub Research Page 6 of 21
About Us
RReennuubb RReesseeaarrcchh is a leading Market Research and Information Analysis Company with
centers at Noida India and Roswell USA. We have long-term experience especially in
international Business-to-Business Researches, Surveys, Business and Consulting. Throughout
the years we have acquired expertise in most market sectors, including Information Technology
(IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking,
Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer
Goods, Logistics, Governmental, Social, and Others.
Our core team is comprised of an experienced people holding graduate, post graduate and
Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information
Technology, Environmental Science and many more. Our research help make the business
decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We
support many blue chip companies by providing them findings and perspectives across a wide
range of markets. Our research reports offer a blend of information insight, analysis and
forecasting that is essential in today’s ultra-competitive markets.
For more information on us or to view any of our sample work you can mail
us at [email protected]
© Renub Research Page 7 of 21
Published
By
RReennuubb RReesseeaarrcchh
1st Floor,
C-86, Sector–10
Noida – 201301
Phone: +91-120-421-9822, 254-5750 (India)
+1-678-302-0700 (USA)
Fax : +91-120-424-9780
Email: [email protected]
www.renub.com
© Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines -
Worldwide Analysis
Renub Research, 2013
Edition 1.0
All rights reserved. This publication is protected
by copyright. No part of it may be reproduced, stored
in a retrieval system or transmitted, in any form or by
any means, electronic mechanical, photocopying,
recording or otherwise without the prior written
permission of the publishers
© Renub Research Page 8 of 21
Table of Contents
1. Executive Summary
2. World Adult Vaccine Analysis & Forecast (2007 – 2020)
2.1 World Adult Vaccine – Market & Forecast
2.2 World Adult Vaccine – Number of Adults Being Vaccinated & Forecast
3. World Adult Vaccine Market Share Analysis & Forecast (2010 – 2020)
3.1 Disease Wise – Market Share & Forecast (2010 – 2020)
3.2 Disease Wise – Percentage of Adults Being Vaccinated Share & Forecast (2010 – 2020)
3.3 Company Wise – Market Share & Forecast (2010 – 2020)
4. World Adult Vaccine Sales – Company Analysis Share & Forecast (2010 – 2020)
4.1 Companies Adult Vaccine Sales – Disease Wise Break up Share & Forecast (2010 – 2020)
4.1.1 GlaxoSmithKline (GSK) - Adult Vaccines Sales Share & Forecast
4.1.2 Sanofi Pasteur - Adult Vaccines Sales Share & Forecast
4.1.3 Merck - Adult Vaccines Sales Share & Forecast
4.1.4 Novartis - Adult Vaccines Sales Share & Forecast
4.2 Adult Vaccine Disease Wise Market Break up - Company Share & Forecast (2010 – 2020)
4.2.1 Influenza Adult Vaccines – Company Market Share
4.2.2 Cervical Cancer/HPV Adult Vaccines – Company Market Share
4.2.3 Hepatitis Adult Vaccines – Company Market Share & Forecast
4.2.4 Pneumococcal Adult Vaccines – Company Market Share & Forecast
4.2.5 Meningococcal Adult Vaccines – Company Market Share & Forecast
4.2.6 DTP (Diphtheria, Tetanus, Pertussis) Adult Vaccines – Company Market Share & Forecast
5. World Adult Vaccine Market – Disease Wise Segmentation Analysis
5.1 Influenza Adult Vaccine Analysis & Forecast (2007 – 2020)
5.1.1 Influenza – Adult Vaccine Market & Forecast
5.1.2 Influenza – Number of Adults Being Vaccinated & Forecast
5.1.3 Influenza – Number of Vaccines Doses & Forecast
5.2 Cervical Cancer/ HPV Analysis (2007 – 2020)
5.2.1 Cervical Cancer/ HPV – Adult Vaccine Market & Forecast
5.2.2 Cervical Cancer/ HPV – Number of Adults Being Vaccinated & Forecast
5.2.3 Cervical Cancer/ HPV – Number of Vaccines Doses & Forecast
© Renub Research Page 9 of 21
5.2.4 Cervical Cancer/HPV - Number of New Cases & Forecast
5.3 Zoster Shingles – Adult Vaccine Analysis (2006 – 2020)
5.3.1 Zoster Shingles – Adult Vaccine Market & Forecast
5.3.2 Zoster Shingles – Number of Adults Being Vaccinated & Forecast
5.3.3 Zoster Shingles – Number of Vaccine Doses & Forecast
5.4 Pneumococcal – Adult Vaccine Analysis (2010 – 2020)
5.4.1 Pneumococcal – Adult Vaccine Market & Forecast
5.4.2 Pneumococcal – Number of Adults Being Vaccinated & Forecast
5.4.3 Pneumococcal – Number of Vaccine Doses & Forecast
5.5 Meningococcal – Adult Vaccine Analysis
5.5.1 Meningococcal – Adult Vaccine Market & Forecast
5.5.2 Meningococcal – Number of Adults Being Vaccinated & Forecast
5.5.3 Meningococcal – Number of Vaccines Doses & Forecast
5.6 Measles, Mumps, Rubella and Varicella (MMRV) – Adult Vaccine Analysis
5.6.1 Measles, Mumps, Rubella and Varicella (MMRV) – Adult Vaccine Market & Forecast
5.6.2 Measles, Mumps, Rubella and Varicella (MMRV) – Number of Adults Being Vaccinated &
Forecast
5.6.3 Measles, Mumps, Rubella and Varicella (MMRV) – Number of Vaccines Doses & Forecast
5.6.4 MMR - Number of New Cases & Forecast
5.7 Hepatitis – Adult Vaccine Market Analysis
5.7.1 Hepatitis – Adult Vaccine Market & Forecast
5.7.2 Hepatitis – Number of Adults Being Vaccinated & Forecast
5.7.3 Hepatitis – Number of vaccine Doses & Forecast
5.7.4 Hepatitis – Number of Acute (New) Cases
5.8 Diphtheria, Tetanus, Pertussis (DTP) – Adult Vaccine Market Analysis
5.8.1 DTP (Diphtheria, Tetanus, Pertussis) – Adult Vaccine Market & Forecast
5.8.2 Diphtheria, Tetanus, Pertussis (DTP) – Number of Adults Being Vaccinated & Forecast
5.8.3 DTP - Number of Vaccines Doses & Forecast
5.8.4 Diphtheria, Tetanus & Pertussis (DTP) - Number of Cases
5.9 Travel and Miscellaneous – Adult Vaccine Market
6. World Adult Vaccine Market – Company Analysis & Strategic Alliances
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline (GSK) - Adult Vaccine Sales & Forecast
6.1.2 Strategic Alliances of GlaxoSmithKline (GSK)
© Renub Research Page 10 of 21
6.2 Sanofi Pasteur
6.2.1 Sanofi Pasteur Vaccines Sales Analysis
6.2.2 Strategic Alliances of Sanofi Pasteur
6.3 Merck
6.3.1 Merck Vaccines Sales Analysis
6.3.2 Strategic Alliances of Merck
6.4 Novartis
6.4.1 Novartis Vaccines Sales Analysis
6.4.2 Strategic Alliances of Novartis
6.5 Pfizer
6.5.1 Pfizer Adult Vaccines Sales & Forecast
6.5.2 Strategic Alliances of Pfizer
6.6 Other Companies
7. World Adult Vaccine – Company Sales Disease Wise Break up & Forecast (2007 – 2020)
7.1 GlaxoSmithKline (GSK) – Adult Vaccines Sales & Forecast
7.1.1 GlaxoSmithKline (GSK) – Influenza Adult Vaccines Sales & Forecast
7.1.2 GlaxoSmithKline (GSK) – Cervical Cancer/HPV Adult Vaccines Sales & Forecast
7.1.3 GlaxoSmithKline (GSK) – Hepatitis Adult Vaccines Sales & Forecast
7.1.4 GlaxoSmithKline (GSK) – DTP Adult Vaccines Sales & Forecast
7.2 Sanofi Pasteur – Adult Vaccines Sales & Forecast
7.2.1 Sanofi Pasteur – Influenza Adult Vaccines Sales & Forecast
7.2.2 Sanofi Pasteur – DTP Adult Vaccines Sales & Forecast
7.2.3 Sanofi Pasteur – Meningococcal Adult Vaccines Sales & Forecast
7.3 Merck – Adult Vaccines Sales & Forecast
7.3.1 Merck – Influenza Adult Vaccines Sales & Forecast
7.3.2 Merck – Cervical Cancer/HPV Adult Vaccines Sales & Forecast
7.3.3 Merck – Zoster Shingles Adult Vaccines Sales & Forecast
7.3.4 Merck – Pneumococcal Adult Vaccines Sales & Forecast
7.3.5 Merck – MMRV Adult Vaccines Sales & Forecast
7.3.6 Merck – Hepatitis Adult Vaccines Sales & Forecast
7.4 Novartis – Adult Vaccines Sales & Forecast
7.4.1 Novartis – Influenza Adult Vaccines Sales & Forecast
7.4.2 Novartis – Meningococcal Adult Vaccines Sales & Forecast
7.5 Pfizer – Adult Vaccines Sales & Forecast
© Renub Research Page 11 of 21
7.5.1 Pfizer – Pneumococcal Adult Vaccines Sales & Forecast
8. World Adult Vaccine Market – Geographical Distribution
8.1 United States – Adult Vaccine Market & Forecast
8.2 North America/Caribbean – Adult Vaccine Market & Forecast
8.3 South America – Adult Vaccine Market & Forecast
8.4 Europe – Adult Vaccine Market & Forecast
8.5 Japan – Adult Vaccine Market & Forecast
8.6 India – Adult Vaccine Market & Forecast
8.7 China – Adult Vaccine Market & Forecast
8.8 Rest of the World (ROW) – Adult Vaccine Market & Forecast
9. Major Vaccine Related Acquisitions (2005-2012)
10. Growth Factors for Adult Vaccines
10.1 Global Immunization Vision and Strategy (GIVS)
10.2 GAVI Model Fuelling Vaccine Manufacturers
10.2.1 The Partnership Model
10.2.2 The Business Model
10.3 Increasing Vaccine Availability in United States
10.4 The Vaccine Safety Data link Project
10.5 The Vaccine Injury Compensation Program
10.6 Transforming of Vaccine Technologies
10.7 Global Vaccine Action Plan by WHO (2011 - 2020)
10.8 Continuous Focus on Effective Communication Strategies
11. Challenges for Adult Vaccines Market
11.1 Hurdles to Optimal use of Licensed Vaccines
11.1.1 Technical Obstacles
11.1.2 Economic obstacles
11.1.3 Cultural Obstacles
11.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
11.2.1 Legal Obstacles
11.2.2 General Technical Barriers
© Renub Research Page 12 of 21
11.2.3 Economic Barriers
11.2.4 Regulatory Barriers
11.3 Shortening the Timeline for Vaccine Development
11.4 Refusal/Resistance to Vaccination
11.4.1 Vaccine Adverse Event Reporting System
11.5 Vaccine Shortages and Delays
11.6 Obstacles in Vaccine Research & Development
11.7 Barriers to New Entrants in the Vaccines Market
© Renub Research Page 13 of 21
List of Figures
Figure 2-1: Worldwide – Adult Vaccine Market (Million US$), 2007 – 2012
Figure 2-2: Worldwide – Forecast for Adult Vaccine Market (Million US$), 2013 – 2020
Figure 2-3: Worldwide – Number of Adults Being Vaccinated with Adult Vaccines (Million), 2007 – 2012
Figure 2-4: Worldwide – Forecast for Number of Adults Being Vaccinated with Adult Vaccines (Million),
2013 – 2020
Figure 3-1: Worldwide – Diseases Wise Adult Vaccine Market Share (Percent), 2010 – 2012
Figure 3-2: Worldwide – Forecast for Diseases Wise Adult Vaccine Market Share (Percent), 2013 – 2020
Figure 3-3: Worldwide – Company Wise Adult Vaccine Market Share (Percent), 2010 – 2012
Figure 3-4: Worldwide – Forecast for Company Wise Adult Vaccine Market Share (Percent), 2013 – 2020
Figure 4-1: Worldwide – GSK Adult Vaccine Sales Share (Percent), 2007 – 2012
Figure 4-2: Worldwide – Forecast for GSK Adult Vaccine Sales Share (Percent), 2013 – 2020
Figure 4-3: Worldwide – Sanofi Pasteur Adult Vaccine Sales Share (Percent), 2010 – 2012
Figure 4-4: Worldwide – Forecast for Sanofi Pasteur Adult Vaccine Sales Share (Percent), 2013 – 2020
Figure 4-5: Worldwide – Merck Adult Vaccine Sales Share (Percent), 2010 – 2012
Figure 4-6: Worldwide – Forecast for Merck Adult Vaccine Sales Share (Percent), 2013 – 2020
Figure 4-7: Worldwide – Forecast for Novartis Adult Vaccine Sales Share (Percent), 2010 – 2012
Figure 4-8: Worldwide – Forecast for Novartis Adult Vaccine Sales Share (Percent), 2013 – 2020
Figure 4-9: Worldwide – Influenza Adult Vaccine Market Share (Percent), 2010 – 2012
Figure 4-10: Worldwide – Forecast for Influenza Adult Vaccine Market Share (Percent), 2013 – 2020
Figure 4-11: Worldwide – Cervical Cancer/HPV Adult Vaccine Market Share (Percent), 2007 – 2012
Figure 4-12: Worldwide – Forecast for Cervical Cancer/HPV Adult Vaccine Market Share (Percent), 2013 –
2020
Figure 4-13: Worldwide – Forecast for Hepatitis Adult Vaccine Market Share (Percent), 2008 – 2012
Figure 4-14: Worldwide – Forecast for Hepatitis Adult Vaccine Market Share (Percent), 2013 – 2020
Figure 4-15: Worldwide – Pneumococcal Adult Vaccine Market Share (Percent), 2010 – 2012
Figure 4-16: Worldwide – Forecast for Pneumococcal Adult Vaccine Market Share (Percent), 2013 – 2020
Figure 4-17: Worldwide – Meningococcal Adult Vaccine Market Share (Percent), 2010 – 2012
Figure 4-18: Worldwide – Forecast for Meningococcal Adult Vaccine Market Share (Percent), 2013 – 2020
Figure 4-19: Worldwide – DTP Adult Vaccine Market Share (Percent), 2010 – 2012
Figure 4-20: Worldwide – Forecast for DTP Adult Vaccine Market Share (Percent), 2013 – 2020
Figure 5-1: Worldwide – Influenza Adult Vaccine Market (Million US$), 2007 – 2012
Figure 5-2: Worldwide – Forecast for Influenza Adult Vaccine Market (Million US$), 2013 – 2020
Figure 5-3: Worldwide – Number of Adults Being Vaccinated with Influenza Vaccine (Million), 2007 – 2012
Figure 5-4: Worldwide – Forecast for Number of Adults Being Vaccinated with Influenza Vaccine (Million),
2013 – 2020
© Renub Research Page 14 of 21
Figure 5-5: Worldwide – Number of Influenza Vaccine Doses (Million), 2007 – 2012
Figure 5-6: Worldwide – Forecast for Number of Influenza Vaccine Doses (Million), 2013 – 2020
Figure 5-7: Worldwide – Cervical Cancer/HPV Adult Vaccine Market (Million US$), 2007 – 2012
Figure 5-8: Worldwide – Forecast for Cervical Cancer/HPV Adult Vaccine Market (Million US$), 2013 –
2020
Figure 5-9: Worldwide – Number of Adults Being Vaccinated with Cancer/HPV Vaccines (Million), 2007 –
2012
Figure 5-10: Worldwide – Forecast for Number of Adults Being Vaccinated with Cancer/HPV Vaccines
(Million), 2013 – 2020
Figure 5-11: Worldwide – Number of Cervical Cancer/ HPV Vaccine Doses (Million), 2007 – 2012
Figure 5-12: Worldwide – Forecast for Number of Cervical Cancer/ HPV Vaccine Doses (Million), 2013 –
2020
Figure 5-13: Worldwide – Zoster Shingles Adult Vaccine Market (Million US$), 2006 – 2012
Figure 5-14: Worldwide – Forecast for Zoster Shingles Adult Vaccine Market (Million US$), 2013 – 2020
Figure 5-15: Worldwide – Number of Adults Being Vaccinated with Zoster Shingles Vaccines (Million),
2006 – 2012
Figure 5-16: Worldwide – Forecast for Number of Adults Being Vaccinated with Zoster Shingles Vaccines
(Million), 2013 – 2020
Figure 5-17: Worldwide – Number of Zoster Shingles Vaccine Doses (Million US$), 2007 – 2012
Figure 5-18: Worldwide – Forecast for Number of Zoster Shingles Vaccine Doses (Million US$), 2013 –
2020
Figure 5-19: Worldwide – Pneumococcal Adult Vaccine Market (Million US$), 2010 – 2012
Figure 5-20: Worldwide – Forecast for Pneumococcal Adult Vaccine Market (Million US$), 2013 – 2020
Figure 5-21: Worldwide – Number of Adults Being Vaccinated with Pneumococcal Vaccines (Million), 2010
– 2012
Figure 5-22: Worldwide – Forecast for Number of Adults Being Vaccinated with Pneumococcal Vaccines
(Million), 2013 – 2020
Figure 5-23: Worldwide – Number of Pneumococcal Vaccines Doses (Million), 2010 – 2012
Figure 5-24: Worldwide – Forecast for Number of Pneumococcal Vaccines Doses (Million), 2013 – 2020
Figure 5-25: Worldwide – Meningococcal Adult Vaccine Market (Million US$), 2010 – 2012
Figure 5-26: Worldwide – Forecast for Meningococcal Adult Vaccine Market (Million US$), 2013 – 2020
Figure 5-27: Worldwide – Number of Adults Being Vaccinated with Meningococcal Vaccines (Million), 2010
– 2012
Figure 5-28: Worldwide – Forecast for Number of Adults Being Vaccinated with Meningococcal Vaccines
(Million), 2013 – 2020
Figure 5-29: Worldwide – Number of Meningococcal Vaccines Doses (Million), 2010 – 2012
Figure 5-30: Worldwide – Forecast for Number of Meningococcal Vaccines Doses (Million), 2013 – 2020
© Renub Research Page 15 of 21
Figure 5-31: Worldwide – MMRV Adult Vaccine Market (Million US$), 2007 – 2012
Figure 5-32: Worldwide – Forecast for MMRV Adult Vaccine Market (Million US$), 2013 – 2020
Figure 5-33: Worldwide – Number of Adults Being Vaccinated with MMRV Vaccines (Million), 2007 – 2012
Figure 5-34: Worldwide – Forecast for Number of Adults Being Vaccinated with MMRV Vaccines (Million),
2013 – 2020
Figure 5-35: Worldwide – Number of MMRV Vaccines Doses (Million), 2007 – 2012
Figure 5-36: Worldwide – Forecast for Number of MMRV Vaccines Doses (Million), 2013 – 2020
Figure 5-37: Worldwide – Hepatitis Adult Vaccine Market (Million US$), 2007 – 2012
Figure 5-38: Worldwide – Forecast for Hepatitis Adult Vaccine Market (Million US$), 2013 – 2020
Figure 5-39: Worldwide – Number of Adults Being Vaccinated with Hepatitis Vaccines (Million), 2007 –
2012
Figure 5-40: Worldwide – Forecast for Number of Adults Being Vaccinated with Hepatitis Vaccines
(Million), 2013 – 2020
Figure 5-41: Worldwide – Number of Hepatitis Vaccines Doses (Million), 2007 – 2012
Figure 5-42: Worldwide – Forecast for Number of Hepatitis Vaccines Doses (Million), 2013 – 2020
Figure 5-43: United States – Reported Acute (New) Cases of Hepatitis A Virus (Number), 2005 – 2011
Figure 5-44: United States – Reported Acute (New) Cases of Hepatitis B Virus (Number), 2005 – 2011
Figure 5-45: Worldwide – DTP Adult Vaccine Market (Million US$), 2010 – 2012
Figure 5-46: Worldwide – Forecast for DTP Adult Vaccine Market (Million US$), 2013 – 2020
Figure 5-47: Worldwide – Number of Adults Being Vaccinated with DTP Vaccines (Million), 2010 – 2012
Figure 5-48: Worldwide – Forecast for Number of Adults Being Vaccinated with DTP (Million), 2013 – 2020
Figure 5-49: Worldwide – Number of DTP Vaccine Doses (Million), 2010 – 2012
Figure 5-50: Worldwide – Forecast for Number of DTP Vaccine Doses (Million), 2013 – 2020
Figure 5-51: Worldwide – Travel and Misc. Adult Vaccine Market (Million US$), 2007 – 2012
Figure 5-52: Worldwide – Forecast For Travel and Misc. Adult Vaccine Market (Million US$), 2013 – 2020
Figure 6-1: Worldwide – GlaxoSmithKline Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 6-2: Worldwide – Forecast for GlaxoSmithKline Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 6-3: Worldwide – Sanofi Pasteur Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 6-4: Worldwide – Forecast for Sanofi Pasteur Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 6-5: Worldwide – Merck Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 6-6: Worldwide – Forecast for Merck Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 6-7: Worldwide – Novartis Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 6-8: Worldwide – Forecast for Novartis Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 6-9: Worldwide – Pfizer Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 6-10: Worldwide – Forecast for Pfizer Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 6-11: Worldwide – Other Companies Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 6-12: Worldwide – Forecast for Other Companies Adult Vaccines Sales (Million US$), 2013 – 2020
© Renub Research Page 16 of 21
Figure 7-1: Worldwide – GSK Influenza Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7-2: Worldwide – Forecast for GSK Influenza Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7-3: Worldwide – GSK Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7-4: Worldwide – Forecast for GSK Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2013
– 2020
Figure 7-5: Worldwide – GSK Hepatitis Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7-6: Worldwide – Forecast for GSK Hepatitis Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7-7: Worldwide – GSK DTP Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7-8: Worldwide – Forecast for GSK DTP Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7-9: Worldwide – Sanofi Pasteur Influenza Adult Vaccines Sales (Million US$), 2009 – 2012
Figure 7-10: Worldwide – Forecast for Sanofi Pasteur Influenza Adult Vaccines Sales (Million US$), 2013 –
2020
Figure 7-11: Worldwide – Sanofi Pasteur DTP Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 7-12: Worldwide – Forecast for Sanofi Pasteur DTP Adult Vaccines Sales (Million US$), 2013 –
2020
Figure 7-13: Worldwide – Sanofi Pasteur Meningococcal Adult Vaccines Sales (Million US$), 2009 – 2012
Figure 7-14: Worldwide – Forecast for Sanofi Pasteur Meningococcal Adult Vaccines Sales (Million US$),
2013 – 2020
Figure 7-15: Worldwide – Merck Influenza Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 7-16: Worldwide – Forecast for Merck Influenza Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7-17: Worldwide – Merck Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7-18: Worldwide – Forecast for Merck Cervical Cancer/HPV Adult Vaccines Sales (Million US$),
2013 – 2020
Figure 7-19: Worldwide – Merck Zoster Shingles Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7-20: Worldwide – Forecast for Merck Zoster Shingles Adult Vaccines Sales (Million US$), 2013 –
2020
Figure 7-21: Worldwide – Merck Pneumococcal Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7-22: Worldwide – Forecast for Merck Pneumococcal Adult Vaccines Sales (Million US$), 2013 –
2020
Figure 7-23: Worldwide – Merck MMRV Adult Vaccines Sales (Million US$), 2007 – 2012
Figure 7-24: Worldwide – Forecast for Merck MMRV Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7-25: Worldwide – Merck Hepatitis Adult Vaccines Sales (Million US$), 2008 – 2012
Figure 7-26: Worldwide – Forecast for Merck Hepatitis Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7-27: Worldwide – Novartis Influenza Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 7-28: Worldwide – Forecast for Novartis Influenza Adult Vaccines Sales (Million US$), 2013 – 2020
Figure 7-29: Worldwide – Novartis Meningococcal Adult Vaccines Sales (Million US$), 2010 – 2012
© Renub Research Page 17 of 21
Figure 7-30: Worldwide – Forecast for Novartis Meningococcal Adult Vaccines Sales (Million US$), 2013 –
2020
Figure 7-31: Worldwide – Pfizer Pneumococcal Adult Vaccines Sales (Million US$), 2010 – 2012
Figure 7-32: Worldwide – Forecast for Pfizer Pneumococcal Adult Vaccines Sales (Million US$), 2013 –
2020
Figure 8-1: United States – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8-2: United States – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8-3: North America/Caribbean – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8-4: North America/Caribbean – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8-5: South America – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8-6: South America – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8-7: Europe – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8-8: Europe – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8-9: Japan – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8-10: Japan – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8-11: India – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8-12: India – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8-13: China – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8-14: China – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 8-15: ROW – Adult Vaccines Market (Million US$), 2007 – 2012
Figure 8-16: ROW – Forecast for Adult Vaccines Market (Million US$), 2013 – 2020
Figure 10-1: Increasing Number of GAVI Suppliers Based in Emerging Markets, 2001 – 2011
Figure 10-2: US – Number of Retail Clinics offering Vaccination (Number), 2007 – 2012
© Renub Research Page 18 of 21
List of Tables
Table 3-1: Worldwide – Share of Adults Being Vaccinated with Adult Vaccines (Percent), 2010 – 2012
Table 3-2: Worldwide – Forecast for Share of Adults Being Vaccinated with Adult Vaccines (Percent), 2013
– 2020
Table 5-1: Cervical Cancer – Region Wise Number of New Cancer Cases (Number), 2009 – 2012
Table 5-2: Cervix – Forecast for Region Wise Number of New Cancer Cases (Number), 2013 – 2018
Table 5-3: Worldwide (By Geographic Region) – Number of Measles Cases (Number), 2001 – 2012
Table 5-4: Worldwide (By Geographic Region) – Number of Mumps Cases (Number), 2001 – 2012
Table 5-5: Worldwide (By Geographic Region) – Number of Rubella Cases (Number), 2001 – 2011
Table 5-6: Worldwide (By Geographic Region) – Number of Diphtheria Cases (Number), 2001 – 2012
Table 5-7: Worldwide (By Geographic Region) – Number of nTetanus Cases (Number), 2001 – 2012
Table 5-8: Worldwide (By Geographic Region) – Number of tTetanus Cases (Number), 2001 – 2012
Table 5-9: Worldwide (By Geographic Region) – Number of Pertussis Cases (Number), 2001 – 2012
Table 9-1: Worldwide – Major Vaccine Related Acquisitions, (2005 – 2012)
Table 10-1: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
Table 10-2: Goal-Level Indicators, 2015 & 2020
Table 10-3: Improvement Strategies or Requirements – the Joint Commission and the Project’s
Collaborating Organizations
© Renub Research Page 19 of 21
Order Form
Scan and e-mail this page to [email protected]. Else you can also fax this form to +91-120-424-
9780
Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to
Format
Report Title: Adult Vaccines Market, Company Adult Vaccines Sales, Country Adult Vaccines
- Worldwide Analysis
Single User (Email from Publisher)
Hard Copy (Mail Delivery)
CD – Rom (Mail Delivery)
Global Site License (Multiple User License)
US$ 1,990 US$ 2,240 US$ 2,090 US$ 2,800
For ordering this report: Three easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.):
http://www.renub.com/report/adult-vaccines-market-company-adult-vaccines-sales-country-
adult-vaccines---worldwide-analysis-126
2) Order by Wire Transfer:
http://www.renub.com/report/wiretransfer.aspx?id=126&pid=1501
To pay by Wire Transfer, please, fill in your contact details in the form below:
© Renub Research Page 20 of 21
Bank Details
Account Name: Renub Research
A/C No.: 109102000023296
Name of Bank: IDBI Bank Ltd.
Swift Code: IBKLINBB010
Bank Address: 4th Floor
Indian Red Cross Building
1 Red Cross Road
Opposite Parliament Street
New Delhi – 110001
India
Contact Information
First Name: Last Name:
Email:
Job Title:
Company:
Address:
City:
Postal/Zip Code:
Country:
Phone:
Mobile:
Fax:
Report Format:
Your message:
© Renub Research Page 21 of 21
3) Order by Check
Please post the check accompanied by this form, to:
Company Address: Renub Research
1st Floor,
C-86, Sector-10
Noida - 201301
Uttar Pradesh
India
Phone: +91-120-421-9822, 424-9780
For free Sample copy report or to view any of our sample work please contact us at
[email protected] or call +91-120-421-9822 (India), +1-678-302-0700 (USA)
Follow Us
Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090
LinkedIn: http://www.linkedin.com/company/renub-research
Twitter: http://twitter.com/RenubResearch